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Opioid use disorder results in increasing mortality every year and is a growing 
concern in the United States. Buprenorphine is a safe and effective evidence-based 
medication to treat opioid use disorder. However, despite this evidence, there are a 
disproportionately low number of providers with the requisite Drug Enforcement Agency 
registration to prescribe buprenorphine, resulting in a significant barrier to access. In 
2016, the Comprehensive Addiction and Recovery Act extended buprenorphine 
prescription privileges to physician assistants and nurse practitioners; however, these 
efforts have been restricted by state regulations. We hypothesize that access to 
buprenorphine is improved in areas where PA/NPs have full scope of practice in 
buprenorphine prescription. By evaluating the impact of the expansion of prescription 
authority to PA/NPs, we can better understand the impact of restricting such authority 
and advance efforts to increase the access to buprenorphine and thereby reduce opioid 
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Chapter 1 – Introduction  
 
1.1 Background 
1.1.1 The Role of Buprenorphine in Treating Opioid Use Disorder 
Opioid misuse and opioid use disorder is a growing concern in the United States 
and worldwide. In 2016 alone, there were 11.5 million people 12 years and older who 
reported nonmedical use of prescription analgesics1. Of this population, 10.9 million 
solely misused opioid analgesics compared to the 948,000 who used heroin1. With 42,249 
deaths from opioid overdose in 2016 and increasing mortality every year2, it is becoming 
more vital than ever to implement evidence-based treatments for opioid use disorder 
(OUD). To address OUD, the Food and Drug Administration (FDA) has approved three 
medications: buprenorphine, methadone, and naltrexone. Buprenorphine, a partial mu 
agonist, has been demonstrated to be a safe and effective medication to treat OUD3-5. It is 
associated with a reduction in HIV risk behavior6,7 and in overdose-related mortality8. 
Moreover, it is invaluable for its availability by prescription from ambulatory centers, 
such as primary care offices, and dispensing up to 30 days via community pharmacies, 
whereas methadone is only available through 1632 federally regulated opioid treatment 
programs (“methadone clinics”)9.  
There are currently a limited number of FDA-approved medications containing 
buprenorphine for the treatment of OUD, typically combined with naloxone to minimize 
diversion, including generic formulations, Bunavail, Suboxone, Zubsolv, and 
buprenorphine-containing transmucosal products10. For the purposes of this study, we 
will use the term “buprenorphine” to refer to all of these medications. 
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1.1.2 Challenges to Buprenorphine Access 
Even with the introduction of a medication like buprenorphine, expanding access 
to all individuals who need it has been challenging. Of the individuals who needed 
treatment for OUD in 2016, only 10.6 percent received treatment1 (This number reflects 
physician prescribers only, as PAs and NPs gained prescriptive authority later). Among 
the many barriers to the medication’s accessibility, of significance is the 
disproportionately low number of providers that are specially qualified to prescribe 
buprenorphine. The Drug Addiction Treatment Act of 2000 (DATA 2000) made it a 
requirement for physicians to complete eight hours of training in order to obtain a waiver 
from the Drug Enforcement Agency (DEA) to prescribe buprenorphine. The waiver 
refers to the Controlled Substances Act and results in a unique DEA registration for the 
waivered prescriber. Once waivered, they are allowed a limited patient capacity of 30 
initially, then up to 275 upon request. Even among waivered physicians, full prescriptive 
potential is not met due to a myriad of concerns including not having enough time for 
more patients and not wanting to prescribe to more patients11-13. The misconception that 
there is a lack of patient demand for buprenorphine is among the barriers as well14. One 
crucial solution to reaching the full potential of buprenorphine, therefore, is increasing 
the number of waivered prescribers, utilizing not only physicians but also the growing 
workforce of physician assistants (PA) and nurse practitioners (NP). The supply of PAs 
and NPs is predicted to increase faster in primary care than that of physicians15, and with 
the accessibility of buprenorphine from primary care offices, it is important to realize the 
full potential of these advanced practice providers in the realm of buprenorphine 
prescription. 
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1.1.3 Physician Assistants and Nurse Practitioners in Buprenorphine Prescription 
Since 2016, the Comprehensive Addiction and Recovery Act (CARA) has 
extended buprenorphine prescriptive privileges to PAs and NPs after 24 hours of training. 
Later in 2018, the Substance Use Disorder Prevention that Promotes Opioid Recovery 
and Treatment for Patients and Communities Act, or the SUPPORT for Patients and 
Communities Act, made these privileges permanent16. Encouragingly, there is high 
interest in prescribing buprenorphine among PAs and NPs17. Nevertheless, the scope of 
practice of PAs and NPs is restricted by individual state regulation, which allows a mix of 
full, restricted, or even no buprenorphine prescriptive privilege. These restrictions may 
have important effects on buprenorphine accessibility for individuals who live in states 
where PAs and NPs do not have the full scope of practice needed for treating OUD. By 
studying how expansion of DEA waivers to PA/NPs is benefitting individuals with OUD, 
we can better understand the dangers of restricting prescription authority and look at what 
steps need to be taken to increase access to buprenorphine to reduce morbidity and 
mortality among those with OUD.  
 
1.2 Statement of the Problem 
 The scope of practice of PAs and NPs in buprenorphine prescription is regulated 
by individual states. This may restrict buprenorphine access for individuals who live in 





1.3 Goals and Objectives  
Ultimately, our goal is to analyze the impact of CARA on buprenorphine access 
in different states. Little is known about the role of PAs and NPs in buprenorphine 
availability; this will be the first analysis of federal efforts such as CARA and the 
SUPPORT for Patients and Communities Act on buprenorphine access through PAs and 
NPs between states where PAs and NPs completely lack buprenorphine prescriptive 
ability and those where they have it. 
 
1.4 Hypothesis 
We hypothesize that, from 2016 to 2018, there has been a statistically significant 
increase in the proportion of waivered providers to total providers in states with waivered 
PAs and NPs versus states with waivered physicians only. 
 
1.5 Definitions and Acronyms  
• Comprehensive Addiction and Recovery Act (CARA): 2016 law that allowed 
qualified PAs and NPs to prescribe buprenorphine 
• Drug Addiction Treatment Act (DATA): 2000 law that allowed qualified 
physicians to prescribe buprenorphine in settings other than opioid treatment 
programs 
• Medication-Assisted Treatment (MAT): “the use of FDA-approved 
medications, in combination with counseling and behavioral therapies, to 
provide a “whole-patient” approach to the treatment of substance use disorders” 
(as defined by Substance Abuse and Mental Health Services Administration) 
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• Opioid Treatment Program (OTP): federally accredited centers providing 
medication for addiction treatment, including methadone and/or buprenorphine, 
for individuals with opioid use disorder 
• Opioid Use Disorder (OUD): “a problematic pattern of opioid use leading to 
clinically significant impairment or distress” (as stated in The Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition) 
• Substance Abuse and Mental Health Services Administration (SAMHSA): 
federally run body with the mission to address substance abuse and mental 
health 
• The Substance Use-Disorder Prevention that Promotes Opioid Recovery and 
Treatment (SUPPORT) for Patients and Communities Act: 2018 law that 
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Chapter 2 – Literature Review 
 
2.1 Introduction 
We conducted a systemic review of the literature using databases including 
PubMed, Cochrane Library, etc. We limited our search to the most recent literature, 
published after 2000. Our systemic review included the following search terms: 
medication-assisted treatment, buprenorphine, opioid use disorder, physician assistant, 
nurse practitioner, access, and CARA. Our search included multiple study designs such 
as cross-sectional studies, randomized controlled trials, and systematic reviews. We 
utilized publically accessible online databases. We restricted our search to studies 
conducted in the English language. 
 
2.2 Review of the Literature  
Since the introduction of CARA, there has been little literature on the 
demonstrable benefits of expanding buprenorphine prescriptive authority to PAs and NPs. 
Despite the growing numbers of PAs and NPs in primary care and their potential for 
improving buprenorphine access, the majority of studies on buprenorphine identified by 
our literature review focused on the physician model for buprenorphine prescription, with 
few studies focusing on PAs and NPs specifically. 
Analytical studies of the contributions of PAs and NPs on buprenorphine access 
are severely lacking. However, we do know that the addition of PAs and NPs increased 
the number of prescribers nationally from 11.0 (only MD) per 100,000 patients in 2016 to 
12.4 per 100,000 patients by the end of 2017 (MD, PA, NP)1. Before we specifically 
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discuss the role of PAs and NPs, we will first consider other efforts that have been taken 
in increasing its access on the federal level. 
 
2.2.1 Federal Initiatives to Expand Access to Buprenorphine 
Since the FDA approval of buprenorphine in 2002, federal initiatives have tried to 
tackle the issue of limited buprenorphine access. From 2003 to 2015, there was an 
increase in the federally regulated opioid treatment programs (OTPs) that provide 
buprenorphine, from 11 percent to 58 percent of OTPs2. Additionally, in 2016, the patient 
limit for prescribers increased from 100 to 2753. Increasing the number of buprenorphine 
treatment slots has been associated with greater amounts of buprenorphine use overall. A 
2015 study showed a statistically significant relationship between the number of 
waivered physicians with a 100-patient limit and increased amounts of buprenorphine use 
per capita4. The same study showed no significant relationship between the number of 
waivered physicians with a 30-patient limit and the amount of buprenorphine prescribed. 
This suggests that one important way of increasing buprenorphine use is allowing 
providers higher patient limits. 
Another challenge is prescriber training and experience with buprenorphine. 
Studies have shown that providers having access to other providers with experience in 
prescribing buprenorphine may increase its prescription5. The Providers Clinical Support 
System (PCSS) is a federally funded program created in an effort to educate and support 
primary care providers in treating OUD, including buprenorphine, through access to 
experts in OUD treatment 6. The required training for buprenorphine prescriptive ability 
is offered through PCSS for physicians, PAs, and NPs. 
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To build upon the efforts of CARA, the SUPPORT for Patients and Communities 
Act became law as of October 24, 2018 to further increase access to medication for 
addiction treatment for people with OUD. Most importantly for PAs and NPs, the ability 
to prescribe buprenorphine, which had been temporary under CARA, became permanent 
under this law. Other efforts included Medicaid reimbursement for medication for 
addiction provided through telehealth and improved funding for pregnant women and 
children affected by OUD7. 
 
2.2.2 Limited Buprenorphine Access in Underserved Communities 
Access to buprenorphine is limited throughout the United States, but it is often 
much more so in certain historically underserved communities. Areas with a higher 
percentage of black, rural, and/or uninsured patients were less likely to have outpatient 
offices providing treatment for substance use disorder that accepted Medicaid8. A recent 
study demonstrated that black patients specifically were less likely to be prescribed 
buprenorphine as compared to other racial groups9. The same study found that the most 
common payment methods for buprenorphine were self-pay and private insurance, 
indicating a huge financial barrier for low-income communities and the need for further 
Medicaid expansion9. Overall, it is evident that buprenorphine access is limited in low-
income communities and warrants particular attention in increasing accessibility to MAT. 
This disproportionate access to buprenorphine is significant to our research as PAs and 
NPs have a well-documented role in providing healthcare to underserved communities 
and imaginably a very valuable role in providing access to buprenorphine. 
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2.2.3 The Role of Physician Assistants and Nurse Practitioners in Communities 
Lacking Access to Buprenorphine 
PAs and NPs are becoming an increasingly vital part of the medical team and 
especially so in communities shown to have reduced access to buprenorphine. It has been 
shown repeatedly that the quality of care provided by primary care advanced practice 
providers such as PAs and NPs is not only comparable to that provided by physicians10 
but also cost-effective11. The increase in numbers of these advanced practice providers is 
expected to be tremendous: from 2016 to 2030, while the number of physicians is 
estimated to grow by 1.1 percent, the numbers of PAs and NPs are estimated to increase 
by 4.3 and 6.8 percent respectively12. In addition, PAs and NPs were found to serve 
communities with greater proportions of Medicaid, uninsured, and minority patients 
when compared to physicians13. Nurse practitioners are practicing at increasing numbers 
in both rural and nonrural areas, as shown by a study which measured their presence in 
primary care offices from 2008 to 201614. The patient population that PAs and NPs serve 
are complicated as well: one study showed an increase between 2008 and 2014 in the 
shared care model (which includes physicians and NPs and/or PAs) for elderly 
populations with multiple comorbidities, patients in rural areas, and health professional 
shortage areas (HPSAs) 15. The same study showed a corresponding decrease in the 
physician model (which includes physicians only). Specifically for patients with OUD, 
the addition of PAs and NPs has been projected to increase the number of patients treated 
with buprenorphine in rural areas by 15.2%16. Unfortunately, there are restrictions on PA 
and NP scope of practice that may hinder their full potential in increasing buprenorphine 
access. 
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2.2.4 Unique Training and Practice Requirements of Physician Assistants and Nurse 
Practitioners  
 In general, the scope of practice of PAs always necessitates collaboration with a 
physician. The scope of practice of NPs can vary widely by state, from supervision or 
collaboration with a physician to fully independent practice. In the case of buprenorphine 
prescription, a waivered PA or NP cannot prescribe unless supervised by or working in 
collaboration with a physician who also has the waiver or fulfills other requirements 
listed in CARA, if required by state law. Before applying for the waiver, the PA or NP 
must complete 24 hours of mandatory training, which is 16 hours more than that required 
for physicians. Moreover, although CARA did extend buprenorphine prescription 
privileges to PAs and NPs, individual state laws nevertheless dictate much of PA and NP 
practice. 
 
2.2.5 The Impact of State-level Policies and Insurance  
 Considering the buprenorphine prescriptive practices of PAs and NPs as a state-
level issue, our search focused on the impacts of various other state policies affecting 
buprenorphine access. Throughout the history of buprenorphine prescription, state-level 
factors have had a powerful influence on its accessibility. Under the Affordable Care Act 
(ACA), individual states have had the option to enroll in Medicaid expansion, extending 
insurance coverage to populations, some of who might benefit from access to 
buprenorphine. As of November 2018, 37 states including the District of Columbia have 
enrolled17. During the early adoption of buprenorphine, a 2008 study predicted a positive 
association between Medicaid coverage of buprenorphine and its prescription18. Later 
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studies confirmed the association between state Medicaid expansion and not only the 
number of buprenorphine prescriptions19 but also the number of waivered physicians20,21. 
This is clear evidence that despite federal initiatives, access to buprenorphine could be 
altered by state level policies. It is also evidence that insurance plays a crucial role in 
obtaining buprenorphine; indeed, insured individuals were 3.3 times more likely to 
receive buprenorphine than those without insurance22. Among privately insured 
individuals between 2003 and 2015, both the total cost and out-of-pocket cost of 
buprenorphine decreased23. Not surprisingly, the situation for patients with Medicaid is 
not as promising. 
 Even among states with Medicaid coverage of buprenorphine, additional 
restrictions have been shown to affect buprenorphine accessibility. Among opioid 
treatment programs, prior authorization of buprenorphine was associated with lower odds 
of offering buprenorphine as a treatment option24. There has also been an upward trend of 
Medicare Part D plans enforcing requirements for prior authorization; one study points 
out the decline of Medicare Part D plans covering buprenorphine without restrictions 
from 89% in 2007 to 35% in 201825. These studies highlight the point that in addition to 
Medicaid coverage by the state, the associated restrictions are significant to 
buprenorphine access as well.  
 Other state resources such as opioid treatment programs21, substance use 
treatment programs21, and state-led guidance on office-based buprenorphine use20 have 
been associated with higher numbers of waivered physicians. Over time, individual state 
policies have had an important impact on buprenorphine access to patients with OUD.  
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 One example of a successful state initiative in improving buprenorphine access is 
an initiative by the Massachusetts Bureau of Substance Abuse Services. This organization 
developed the Massachusetts Collaborative Care Model, in which nurses took a central 
role among primary care physicians in the care of patients with OUD. In this novel model, 
the nurse care manager served as the connection between waivered physicians and 
patients. The office-based opioid treatment (OBOT)-Collaborative Care Model was 
adapted into community health centers, ultimately increasing the enrollment of patients 
with OUD in community health centers and the numbers of waivered physicians26. This 
initiative with its collaborative and novel practices may be advantageous and much 
needed for this otherwise under-accessed medication and can serve as a model for other 
states. As PAs and NPs become an integral part of the medical team, it is important to 
include them in strategies to broaden accessibility to buprenorphine. 
 On the other hand, two states stand out in their uniquely strict monitoring of 
buprenorphine prescription. For example, Tennessee currently only allows physicians to 
prescribe buprenorphine, completely excluding PAs and NPs from using this medication 
to treat OUD.27 In Kentucky, physicians and NPs may prescribe buprenorphine but PAs 
may not27. Compared to the national opioid-related death rate of 14.6 per 100,000 persons, 
Tennessee and Kentucky are burdened with significantly higher rates at 19.3 and 27.9, 
respectively, as of 201728. These two states represent cases where it may be especially 





2.2.6 Categorization of States for Physician Assistants and Nurse Practitioners 
Despite the wide variability of state-based scope of practice, states can be 
categorized in terms of the scope of practice of PAs and NPs. Generally, for most states, 
the scope of practice of PAs is decided at the practice level, rather than at the state level29. 
PAs, by training, are required to practice with a supervising MD. On the other hand, the 
scope of practice of NPs is organized into “restricted”, “reduced” and “full” by the 
American Association of Nurse Practitioners30, where states with restricted or reduced 
NP scope of practice requires supervision or collaboration with MDs. This categorization 
has been used in studies to describe the scope of practice of NPs14. In a recent study, the 
scope of practice of PAs and NPs throughout the United States was defined as “less 
restrictive” and “more restrictive”31. For NPs, “less restrictive” states did not require 
physician oversight for medication prescription whereas “more restrictive” states did. For 
PAs, “less restrictive” states had 5-6 essential elements of PA practice as defined by the 
American Association of Physician Assistants whereas “more restrictive” states had less 
than 531. This study found a significant association between scope of practice and the 
waivered status of NPs, with a statistically significant mean difference of 3.14 percentage 
points (95% CI, 2.05-4.23) between the less restrictive and more restrictive states for NPs. 
We took these categorizations into consideration when analyzing the chosen states in the 
study. 
 
2.3 Review of Relevant Methodology  
Due to the novelty of our study and the lack of similar studies with PAs and NPs 
functioning as clinicians in OUD treatment, our study methodology was challenging. It 
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has merely been 2 years since PAs and NPs gained buprenorphine prescriptive privileges 
through CARA 2016. Consequently, much of the literature to this day has focused on the 
physician as the sole clinician providing medication-assisted treatment. The role of PAs 
and NPs in buprenorphine prescription in the realm of facing the epidemic of opioid 
addiction has yet to be fully observed.  
The recent study by Spetz et al. was the first to examine a relationship between 
state restrictions on PA and NP scope of practice and the proportion of waivered PAs and 
NPs31. Their study designates scope of practice of NPs and PAs as the independent 
variable. The dependent variable is the mean proportions of waivered providers per state 
by the provider type and scope of practice, similarly to our study. For our study, we 
designated our key independent variable as the ability of PAs and NPs to prescribe 
buprenorphine. We wanted to distinguish states like Tennessee and Kentucky from other 
states that may have differences in scope of practice but do not have specific restrictions 
for buprenorphine prescription by PAs and NPs.  
Therefore, our key independent variable is the ability of PAs and NPs to prescribe 
buprenorphine as a binary variable. The key independent variable in the study by Wen et 
al. 32 is the state implementation of Medicaid expansion, which is very similar to our 
independent variable in that both studies analyze the effects of a state-level restriction. 
Then, based on our literature review, we selected covariates that have been 
documented to have an association with buprenorphine availability or OUD. Our 
covariates include Medicaid expansion, prior authorization, urbanicity, number of OUD-
related deaths, and the number of OTPs providing buprenorphine. The adjustment of the 
covariates and further design of multivariable linear regression was loosely designed 
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from two different studies: a study by Mohlman et al. which used a multivariable linear 
regression model33 and a study by Haffajee et al. which used a multivariate logistic 
regression model34. 
Finally, rather than looking at data solely from 2018, we wanted to analyze the 
trend over time since CARA was passed in the proportion of waivered providers to total 
providers. This was our reasoning in designing a repeated cross-sectional study from 
2016 to 2018. 
 
2.4 Conclusion 
Through our literature review, we were able to identify both current efforts to 
improve buprenorphine access and restrictions to buprenorphine access. There are federal 
initiatives in place with the goal of improving buprenorphine access, such as recent 
increases in OTPs providing buprenorphine, increases in providers’ patient limit to 275, 
and the Providers Clinical Support System, which provides support for primary care 
providers in OUD treatment. In addition, the SUPPORT for Patients and Communities 
Act passed in 2018 made buprenorphine prescriptive ability for PAs and NPs permanent, 
among other achievements.  
Despite these achievements, there are yet many limitations to buprenorphine 
access that we found through our literature review. There is disproportionate access to 
buprenorphine for black, rural, and uninsured patients. PAs and NPs have been shown to 
serve these patient communities with a demonstrated quality of care and cost-
effectiveness. However, PA and NP practice is limited. They may only prescribe 
buprenorphine if the collaborative physicians are waivered, and individual state policies 
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may restrict their ability to prescribe this drug altogether. Overall, individual states have 
significant control of buprenorphine access, with varying levels of Medicaid expansion, 
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Chapter 3 – Methods  
 
3.1 Study design 
We will conduct an analysis of a repeated cross-sectional data from 2016 to 2018, 
to analyze changes over time in numbers of waivered providers in four representative 
states. 
 
3.2 State Profiles  
We chose four states—Tennessee, Kentucky, Ohio, and West Virginia—each 
representing varying levels of PA and NP scope of practice. The individual state profiles, 
in order of most to least restrictive, are described below. Table 1 displays MD, PA, and 
NP buprenorphine prescriptive ability for each state. 
Tennessee is the only state in the United States in which neither PAs nor NPs can 
prescribe buprenorphine. Only MDs are able to prescribe buprenorphine in this state. 
Tennessee is further unique in that it is one of the few states that have not accepted 
Medicaid expansion. Tennessee requires prior authorization for buprenorphine use. In 
this state, NPs have restricted practice, which requires physician supervision1. 
Kentucky allows NPs to prescribe buprenorphine. MDs and NPs prescribe 
buprenorphine in this state. Kentucky has accepted Medicaid expansion and requires 
prior authorization for buprenorphine use. In this state, NPs have reduced practice, which 
requires physician collaboration1. 
Ohio allows both PAs and NPs to prescribe buprenorphine along with MDs. PA 
practice is determined at the practice level and requires physician supervision, similarly 
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to NP practice requiring physician collaboration in this state. Ohio has accepted Medicaid 
expansion and requires prior authorization for buprenorphine use. In this state, NPs have 
reduced practice, which requires physician collaboration1. 
West Virginia allows both PAs and NPs to prescribe buprenorphine along with 
MDs. PA practice is determined at the practice level and requires physician supervision, 
similarly to NP practice requiring physician collaboration in this state. West Virginia has 
accepted Medicaid expansion and requires prior authorization for buprenorphine use. In 
this state, NPs have reduced practice, which requires physician collaboration1. 
Table 1. Buprenorphine prescriptive ability by MD, PA, NP by state 
 Buprenorphine Prescriptive Ability 
State MD PA NP 
Tennessee Yes No No 
Kentucky Yes No Yes 
Ohio Yes Yes Yes 
West Virginia Yes Yes Yes 
 
 
3.3 Study Variables  
The primary independent variable of interest is the ability to prescribe 
buprenorphine by PAs and NPs within each state. This will be represented as a binary 
variable.  
Table 2 lists the covariates that will be included in our study. Covariates will 
include: (1) Medicaid expansion, (2) prior authorization, (3) urbanicity, (4) number of 
OUD-related deaths, and the (5) number of OTPs providing buprenorphine. Medicaid 
expansion and prior authorization will be represented as a binary variable. Urbanicity will 
be represented as a binary variable, with the state being defined as metropolitan or 
nonmetropolitan as a sum of their representative counties. The number of OUD-related 
deaths will be a continuous variable, represented as a proportion over 100,000 residents. 
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The number of OTPs providing buprenorphine will be a continuous variable, represented 
as a proportion over 100,000 residents as well. 
 Our dependent variable will be a continuous variable representing the proportion 
of waivered providers per total providers in that state. This will be further organized by 
the patient capacity of the providers: up to 30, 100, or 275 patients. 
 We will also include a secondary outcome variable: the amount of buprenorphine 
dispensed. 















# of OTPs 
providing 
buprenorphine* 
Tennessee No Yes    
Kentucky Yes Yes    
Ohio Yes Yes    
West 
Virginia 
Yes  Yes    
*Data to be input in the future upon study completion 
 
3.4 Data Collection 
All of our data will be collected from publically accessible, online databases.  
For the primary independent variable, the ability of PAs and NPs in prescribing 
buprenorphine is stated by the Scope of Practice Policy website maintained by the 
National Conference of State Legislatures (NCSL) and the Association of State and 
Territorial Health Officials (ASTHO)2.  
 For the multiple covariates, the Kaiser Family Foundation provides up to date 
data on whether states have or have not adopted Medicaid expansion3. The American 
Society of Addiction Medicine (ASAM) provides State Medicaid Reports with 
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information on whether individual state policies require prior authorization for 
buprenorphine4. The urbanicity of the states will be based on the Rural-Urban Continuum 
for counties within the state as defined the United States Department of Agriculture5. The 
sum of the urbanicity of the individual counties will be calculated to determine urbanicity 
for the entire state. The number of OUD-related deaths is provided by the CDC Wide-
ranging Online Data for Epidemiologic Research (WONDER) database6. The number of 
OTPs providing buprenorphine will be obtained from the National Survey of Substance 
Abuse Treatment Services (N-SSATS) by state and year7. 
For the dependent variable, SAMHSA provides a database of all waivered 
providers, including physicians, PAs, and NPs for each state8. The sum totals of waivered 
providers, organized by specific patient limits will also be provided by SAMHSA. The 
total numbers of providers will be obtained from the Area Health Resources Files (AHRF) 
maintained by the Health Resources and Services Administration9. Both the total number 
of waivered providers and the proportion of waivered providers to total providers will be 
provided in Tables 3-5. 
For the secondary outcome variable, the amount of buprenorphine dispensed by 
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No West 
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No  Tennessee       
Yes (NP) Kentucky       
Yes (PA, NP) Ohio       
Yes (PA, NP) West 
Virginia 
      
*Proportion of waivered providers over total providers  
 
3.5 Statistical Analysis 
We will use descriptive statistics to organize our data collected from online 
databases. Next, we will use multivariable linear regression to analyze differences in the 
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dependent variable, the proportion of waivered providers per total providers in that state, 
while adjusting for the multiple covariates. Finally, we will use one-way ANOVA to 
evaluate for trends over time, from 2016 to 2018. We will consider p < 0.05 to be 
statistically significant. Table 6 shows the independent variables and their associated 
estimated regression coefficients with p values. 
Table 6. Multivariate linear regression of the proportion of waivered providers 
Independent Variable Estimated Regression 
Coefficient 
p 
PAs and NPs’ buprenorphine prescriptive 
authority* 
  
Medicaid expansion   
Prior authorization   
Urbanicity   
OUD-related deaths   
OTPs providing buprenorphine   
*Key independent variable 
 
3.6 Limitations 
 Our study has a few limitations. First, the list of providers provided by SAMHSA 
includes those that may not be practicing or prescribing buprenorphine to the fullest 
capacity. The listing is voluntary, so there may be waivered providers who have chosen 
not to be included in the list. Therefore, we are relying on the database to provide a 
reasonable approximation. In addition, different products containing buprenorphine may 
have different availability and insurance coverage within each state, although we 
anticipate that this will have a small effect on buprenorphine availability overall. We 
chose covariates based on our own literature review, so we are relying on our literature 
review on whether our chosen covariates are appropriate or essential covariates were left 
out. Using a multivariable linear regression as our study design will help to adjust for the 
known confounders.  
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 Our findings represent a section of the United States with variability in 
buprenorphine prescription by PAs and NPs. More studies will need to be done to 
observe their role in buprenorphine prescription throughout the United States. 
Lastly, as this is a cross sectional study, our findings will show correlation 
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Chapter 4 – Conclusion 
 
4.1 Advantages 
 Our study has a number of advantages. First, it is the first analytical study to 
compare states with and without PA/NP buprenorphine prescriptive ability in the role in 
buprenorphine access. It can be repeated in future years for ongoing surveillance of the 
role of PAs and NPs, in impacting access to buprenorphine access, especially as state 
policies change over time. With the repeated cross-sectional design, it is possible to view 
the changes in buprenorphine access over time, as opposed to a static cross-sectional 
study. Moreover, with this study design, it can be conducted in “real time”  as the data 




 Our study does have a few disadvantages. First, its generalizability is limited as 
we looked at four specific states; for this same reason, randomization is not possible. 
There are county-level differences within the states, which we did not address in our 
study as our focus was on state-level policies that affected buprenorphine access. Second, 
the findings will represent correlation, not causation due to our study design. Furthermore, 
there are multiple confounders that we will adjust for. As previously discussed, there is 
always the possibility that we left out essential covariates as it is based purely on our 
literature review.  
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4.3 Clinical and Public Health Significance 
 Increasing accessibility to OUD treatment, such as buprenorphine, is a topic that 
is gaining substantial attention, as evidenced by recent legislation such as CARA and 
SUPPORT for Patients and Communities Act. 
 We anticipate that our findings will help to inform state and federal policy 
changes to improve buprenorphine access by demonstrating the ongoing and future roles 
of PAs and NPs in expanding access to effective OUD treatment. It is already 
documented that state level policies can have major effects on buprenorphine access. Our 
study can inform political efforts designed to impact legislation in the states where PAs 
and NPs cannot prescribe buprenorphine. It is important to continue to recognize and 
document the benefits of utilizing the PAs and NPs to their full potential. Even in states 
where PAs and NPs already have the ability to become waivered, our study can raise 
awareness of the importance of the waiver process to PAs, NPs, and the physicians they 
work with.  
 More broadly, our findings may provide an example of how limitations on the 
scope of practice of PAs and NPs in certain states can have a detrimental effect on 
patients who lack access to healthcare. Moving forward, not only will it be critical to 
increase access to buprenorphine through PAs and NPs but also to support other states in 
expanding their Medicaid programs, decreasing restrictions such as prior authorization, 
and making it more efficient to obtain higher patient limits. A combination of these 
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